Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 1, 2013, Pages 105-112

  de Boysson, Hubert ^a   Boutemy, Jonathan ^a   Creveuil, Christian ^a   Ollivier, Yann ^a   Letellier, Philippe ^a   Pagnoux, Christian ^b   Bienvenu, Boris ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cyclophosphamide; Giant cell arteritis; Glucocorticoid dependence; Glucocorticoid iatrogeny

Indexed keywords

CYCLOPHOSPHAMIDE; DAPSONE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INFUSION; DRUG RESPONSE; DRUG WITHDRAWAL; ERYSIPELAS; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN TISSUE; INFECTION; LIVER FAILURE; MALE; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; REMISSION; SKIN TOXICITY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VASCULITIS;

CYCLOPHOSPHAMIDE; GIANT-CELL ARTERITIS; GLUCOCORTICOID DEPENDENCE; GLUCOCORTICOID IATROGENY;

AGED; AGED, 80 AND OVER; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISONE; TREATMENT OUTCOME;

EID: 84881543974     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.12.023     Document Type: Article

References (32)

1. Wilkinson I.M., Russell R.W. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 1972, 27:378-391.
2. Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002, 347:261-271.
3. Nesher G., Sonnenblick M., Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994, 21:1283-1286.
4. Kotter I., Henes J.C., Wagner A.D., Loock J., Gross W.L. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012, 30:S114-S129.
5. Hachulla E., Boivin V., Pasturel-Michon U., Fauchais A.L., Bouroz-Joly J., Perez-Cousin M., et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001, 19:171-176.
6. Uddhammar A., Eriksson A.L., Nystrom L., Stenling R., Rantapaa-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002, 29:737-742.
7. Cantini F., Niccoli L., Salvarani C., Padula A., Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001, 44:2933-2935.
8. De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986, 45:136-138.
9. Jover J.A., Hernandez-Garcia C., Morado I.C., Vargas E., Banares A., Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:106-114.
10. Demaziere A. Dapsone in the long-term treatment of temporal arteritis. Am J Med 1989, 87:3.
11. Mahr A.D., Jover J.A., Spiera R.F., Hernandez-Garcia C., Fernandez-Gutierrez B., Lavalley M.P., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789-2797.
12. de Vita S., Tavoni A., Jeracitano G., Gemignani G., Dolcher M.P., Bombardieri S. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med 1992, 232:373-375.
13. Henes J.C., Mueller M., Pfannenberg C., Kanz L., Koetter I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011, 29:S43-S48.
14. Loock J., Henes J.C., Kötter I., Witte T., Lamprecht P., Schirmer M., et al. Treatment of refractory giant cell arteritis with cyclophosphamide. A retrospective analysis of 35 patients from three tertiary care centers. Clin Exp Rheumatol 2012, 30:S70-S76.
15. Quartuccio L., Maset M., De Maglio G., Pontarini E., Fabris M., Mansutti E., et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford) 2012, 51:1677-1686.
16. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., K de Groot, Gross W., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009, 68:310-317.
17. Hunder G.G., Bloch D.A., Michel B.A., Stevens M.B., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990, 33:1122-1128.
18. Canton C.G., Bernis C., Paraiso V., Barril G., Garcia A., Osorio C., et al. Renal failure in temporal arteritis. Am J Nephrol 1992, 12:380-383.
19. Puerto B., Noval S., Veiga C., Contreras I., Mateos E. Apical orbital inflammation in giant cell arteritis. Arch Soc Esp Oftalmol 2007, 82:47-49.
20. Alba M.A., Mena-Madrazo J.A., Reyes E., Flores-Suarez L.F. Giant cell arteritis in Mexican patients. J Clin Rheumatol 2012, 18:1-7.
21. Bhatia A., Ell P.J., Edwards J.C. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005, 64:1099-1100.
22. Buttner T., Heye N., Przuntek H. Temporal arteritis with cerebral complications: report of four cases. Eur Neurol 1994, 34:162-167.
23. Calguneri M., Cobankara V., Ozatli D., Guler G., Apras S., Pay S., et al. Is visual loss due to giant cell arteritis reversible?. Yonsei Med J 2003, 44:155-158.
24. de la Casa Monje R., Barbado Hernández F.J., Peña Sánchez de Rivera J.M., Domínguez Castellano A., Sendino Revuelta A., González-Anglada I., et al. Giant-cell arteritis: the clinico-biological manifestations and the complications secondary to steroid treatment. An Med Interna 1991, 8:161-165.
25. Gouet D., Marechaud R., Le Berre D., Alcalay M., Becq-Giraudon B., Boissonnot L., et al. Prognosis of treated temporal arteritis. Retrospective study of 87 cases. Presse Med 1986, 15:603-606.
26. Peña Sánchez de Rivera J.M., Barbado Hernández F.J., Redondo Sánchez C., Vázquez Rodríguez J.J. Is cyclophosphamide useful in the treatment of giant cell arteritis?. Med Clin (Barc) 1986, 86:306.
27. Roelcke U., Eschle D., Kappos L., Moschopulos M., Laeng R.H., Buettner U.W. Meningoradiculitis associated with giant cell arteritis. Neurology 2002, 59:1811-1812.
28. Ruegg S., Engelter S., Jeanneret C., Hetzel A., Probst A., Steck A.J., et al. Bilateral vertebral artery occlusion resulting from giant cell arteritis: report of 3 cases and review of the literature. Medicine (Baltimore) 2003, 82:1-12.
29. Sailler L.J., Porte L., Ollier S.M., Astudillo L.M., Couret B.G., Catalaa I., et al. Giant cell arteritis and spinal cord compression: an overlap syndrome?. Mayo Clin Proc 2006, 81:89-91.
30. Serradell S., Laiz A., Castano C., de Llobet J.M. Usefulness of angioplasty in a patient with biopsy-proven giant cell arteritis and severe stenosis of the superior mesenteric artery. J Rheumatol 2006, 33:1204-1205.
31. Proven A., Gabriel S.E., Orces C., O'Fallon W.M., Hunder G.G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708.
32. Alba M.A., Garcia-Martinez A., Espigol-Frigole G., Tavera-Bahillo I., Prieto-Gonzalez S., Hernandez-Rodriguez J. Differences in clinical presentation and outcome in patients with early versus late onset giant-cell arteritis (GCA): analysis of 94 patients. Ann Rheum Dis 2012, 71(Suppl 3):230.